Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on TIZIANA LIFE SCIENCES PLC. We currently have 11 research reports from 3 professional analysts.
|24Mar17 07:00||RNS||Exercise of Warrants & Issue of Equity|
|16Jan17 07:00||RNS||Warrant Expiry - Reminder|
|03Jan17 07:00||RNS||Tiziana Life Sciences in-licenses NI-1201|
|16Nov16 07:00||RNS||New Data with Foralumab|
|07Nov16 12:29||RNS||Grant of options|
|29Sep16 07:00||RNS||Half-year Report|
|15Sep16 07:00||RNS||Confirmation of Capital Reduction|
Frequency of research reports
Research reports on
TIZIANA LIFE SCIENCES PLC
TIZIANA LIFE SCIENCES PLC
15 Mar 17
With most investors waiting for the Fed to deliver its expected rate hike from 0.75% to 1.00%, which is due at 18:00hrs GMT today, traders instead focussed on Saudi Arabia notifying OPEC that it raised output back to above 10 million barrels a day in February. This reversed about one-third of the cuts it made the previous month, having trimmed more than required in January with a view to leading the way in the international production agreement that was designed to re-balance world markets. With Fed Funds still indicating the chance of the rate cut above 90%, however, the principal focus has reverted from the rate itself to Janet Yellen’s forward looking statements and, in particular, whether she flags the possibility of either a more aggressive stance or perhaps the need to increase her guided number of moves in 2017 from three to four during today’s FOMC deliberations. So it was the S&P 500 energy sector that was responsible for leading US markets downward yesterday, falling 1.8% in early trade as crude dropped 2.1% to US$47.40/bb on its way for its seventh consecutive daily decline before recovering somewhat during the Asian session. Amid severe East Coast winter storms, this helped push the three principal US equity indices into the red, all with similar minor negative moves in otherwise featureless trading. The sell-off in the oil market stoked demand for government bonds, reversing early losses as investors sought a safe haven, sufficiently to pressure the 10-year Treasury yield down to 2.593% from the 2.609% it reached on Monday, its highest settlement since 2014. Asian equities again traded in a very narrow range, with only the ASX registering a modest gain, while the other regional markets moved fractionally negative in low volume trading. With an eye on the Dutch elections the Stoxx Europe 600 declined 0.4% yesterday, with traders eyeing the outcome during the early hours of Thursday morning primarily to confirm late reports that support for the Geert Wilders’ Far Right party has indeed slumped, as this will likely set expectations for the highly sensitive French Presidential election which is due to take place on 23rd April. While Sterling appeared to ignore Scotland's chief minister Nicola Stugeon calling for another Referendum on leaving the U.K., traders instead anticipated the continuation of the Bank of England’s dovish tone at its policy meeting on Thursday, chasing the currency down 0.6% against the US$ to an eight-week low. UK macro news due for release today includes the ILO Unemployment Rate and Average Earnings for January, while the EU provides its Q4 Employment Change numbers. The US is scheduled to detail a large batch of statistics, including MBA Mortgage Applications, February Retail sales, Consumer Prices, Business inventories and the NAHB Housing Market Index, although all this will be overshadowed by the FOMC’s Economic report and Fed’s rate decision that follows. UK corporates are also due to provide earnings or trading updates include Biffa (BIFF.L), Robert Walters (RWA.L), STM Group (STM.L), Marshalls (MSLH.L) and Hikma Pharmaceuticals (HIK.L). London equities are expected quietly this morning, with the FTSE-100 expected to regain most of yesterday’s modest losses, rising as much as 10 points in early trading.
04 Jan 17
Has Trumponomics scored its first success for American workers? Yesterday’s decision from Ford to cancel its planned US$1.6bn Mexico plant and instead invest US$700m in Michigan following the President-elect’s criticism of rival General Motors with the treat of a “big border tax” on compact cars re-imported from neighbouring countries, suggests maybe it has. The Dollar also celebrated yesterday’s release of strong macro data, including Maufacturing PMI, ISM and Construction figures, which powered the greenback to a 14-year high against the international basket. US stocks celebrated the news with the Dow Jones rising 175-point rise in early trading, reflecting optimism that equities will be sure fire winners in an expanding, less regulated environment as the ending of the bond market’s long-run bull becomes all but confirmed. While some of the gains were given back before the session close, all principal indices ended their first trading day of 2017 showing impressive gains particularly in telecom and healthcare with traders convinced psychological resistance to breaking Dow’s 20,000 barrier will be broken very shortly. Asia also put in a good performance, with Japan more than catching up with its neighbours following its four-day holiday weekend by putting in a gain of 2.5% driven primarily by financials and export stocks, leaving only the Hang Seng fractionally in the negative after Tuesday’s strong rise. A good batch of macro data is due for release today, with investor eyes mainly focussed on the Eurozone’s Consumer Price Index figure for December, which is expected to come out at around 1.0% (from 0.6% last time) thereby providing confirmation that the major western economies are finally returning to a phase of rising inflation. The UK will provide the BRC Shop Price Index, PMI Construction numbers for December plus November’s Consumer Credit and Mortgage Approvals, while the US is scheduled to detail MBA Mortgage Applications and FOMC Minutes. Amongst corporates, the eagerly awaited Christmas Trading Statement from Next (NXT.L) is due for release this morning along with Ryanair (RYA.L) December Passenger Figures, while earnings or updates are also anticipated from B&M European Value (BME.L) and Staffline Group (STAF.L). The FTSE-100 is seen taking its opening confidence from the overnight markets and expected to rise around 12 points in early morning trading.
17 Nov 16
"The Fed's Patrick Harker yesterday spelt out just how complex policy on interest rates has now become. Janet Yellen's own testimony this afternoon, which is seen as key to December's FOMC decision, will have to grapple with all the new uncertainties injected by the President-elect, ranging from regressive tax cuts, booming infrastructure spending, financial deregulation and cuts in federal spending. No easy task, even if the markets appear more convinced than ever that the first hike since 2006 will be delivered next month and that this will be the first of a series of such moves over the subsequent 18 or so months as inflation climbs. The recent phase of asset repricing, nevertheless, took a breather yesterday, with all principal markets making only fractional movements. The Dow Jones broke its record run to drift into the red as financials retrenched, while momentum in technology stocks meant the NASDAQ still managed to close modestly up. Asia also put in just marginal movements across the board, as oil prices went lower on weekly data detailing a large rise in inventories, while the Bank of Japan surprised traders with its plans to buy unlimited JGBs at fixed rates in its latest daily market operation. The latter, of course, being seen as it effort to ensure domestic rates do not find themselves shackled to the US T-bill's upward movements. Today, the UK is due to release retail sales figures while the CML provides mortgage lending data; Eurozone inflation numbers are also expected this morning. Clearly the principal event of the day, however, will be Janet Yellen's Testimony on Capitol Hill which is due to commence at 10:00hrs EST and likely overshadow speeches also due from the Fed's William Dudley and Lael Brainard; the US is due to release inflation, weekly jobless claims and export statistics this afternoon as well. Another busy day for UK corporates, with earnings or trading updates scheduled from the likes of CRH (CRH.L), Great Portland Estates (GPOR.L), Johnson Matthey (JMAT.L), Kier Group (KIER.L), Premier Oil (PMO.L), Royal Mail (RMG.L), Shanks (SKS.L), Ted Baker (TED.L), TT Electronics (TTG.L) and Watkin Jones (WJG.L). The FTSE-100 is expected to open virtually unchanged." - Barry Gibb, Research Analyst
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
Interim results lead to upgrades
27 Mar 17
Bioventix reported a strong set of interim results with revenues increasing by 32% (c.12-17% at constant exchange rates (CER)), driven largely by the continued roll-out of its customers’ Vitamin D assay products. This, in turn, led to a 41% increase in pre-tax profits and a 40% increase in adjusted EPS; which is reflective of the operational gearing of the business. We are upgrading our adjusted EPS to 78.7p (+5%) and, consequently, are raising our target price to 1750p. At this price level, the shares would trade on a 22.4x FY 2018 P/E and an EV/EBITDA of 17x. We await confirmation of Siemen’s high sensitivity troponin assay launch, expected in FY 2018.
27 Mar 17
Elecosoft* (ELCO): Steadily building profits (CORP) | Bioventix* (BVXP): Interim results lead to upgrades (CORP) | Hurricane Energy (HUR): Halifax discovery (BUY) | KBT Business Technology* (KBT): interims and contract win (CORP) | Independent Oil & Gas* (IOG): Licence updates (CORP)
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Sinclair Pharma - Aesthetically Positioned to Continue Double-Digit Growth
23 Mar 17
With an innovative and differentiated product portfolio of injectable devices addressing the fast-growing aesthetics market, Sinclair is best positioned to continue to achieve double-digit revenue growth in the medium term.
N+1 Singer - Futura Medical - Licensing deal for CSD500 in Portugal
22 Mar 17
The agreement with F Lima further extends the market reach of CSD500, Futura’s erectogenic condom, and brings the total number of distribution partners to eight. The deal is in line with the company’s stated strategy of partnering with leading regional players in the consumer products space. We expect the condom to be launched in Portugal later this year. We retain a positive stance.